Ilia I. Ouspenski

Array ( [id] => 17928369 [patent_doc_number] => 20220323494 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => Novel Control Switch [patent_app_type] => utility [patent_app_number] => 17/283061 [patent_app_country] => US [patent_app_date] => 2019-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16117 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283061 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16369092 [patent_doc_number] => 10800833 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-13 [patent_title] => Co-stimulatory domains for use in genetically-modified cells [patent_app_type] => utility [patent_app_number] => 16/600074 [patent_app_country] => US [patent_app_date] => 2019-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 59 [patent_no_of_words] => 28989 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16600074 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15863083 [patent_doc_number] => 20200138945 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => Monoclonal Antibodies to Programmed Death 1 (PD-1) [patent_app_type] => utility [patent_app_number] => 16/600272 [patent_app_country] => US [patent_app_date] => 2019-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46100 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16600272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16948190 [patent_doc_number] => 20210206881 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/579321 [patent_app_country] => US [patent_app_date] => 2019-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15825 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16579321 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15678395 [patent_doc_number] => 20200093861 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => ANTIGEN BINDING RECEPTOR FORMATS [patent_app_type] => utility [patent_app_number] => 16/576586 [patent_app_country] => US [patent_app_date] => 2019-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55763 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16576586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16238291 [patent_doc_number] => 20200255525 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => PD-1 BINDING PROTEINS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/573322 [patent_app_country] => US [patent_app_date] => 2019-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 87153 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16573322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17997861 [patent_doc_number] => 11498955 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-15 [patent_title] => SPD-1 variant# FC fusion proteins [patent_app_type] => utility [patent_app_number] => 16/569105 [patent_app_country] => US [patent_app_date] => 2019-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 123 [patent_figures_cnt] => 115 [patent_no_of_words] => 39437 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16569105 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17672722 [patent_doc_number] => 20220185889 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY PROFILING [patent_app_type] => utility [patent_app_number] => 17/275117 [patent_app_country] => US [patent_app_date] => 2019-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14006 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17275117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15264843 [patent_doc_number] => 20190381155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY [patent_app_type] => utility [patent_app_number] => 16/555586 [patent_app_country] => US [patent_app_date] => 2019-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34199 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16555586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17170413 [patent_doc_number] => 20210324083 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => METHODS AND COMPOSITIONS COMPRISING B7H3 CHIMERIC ANTIGEN RECEPTORS [patent_app_type] => utility [patent_app_number] => 17/271813 [patent_app_country] => US [patent_app_date] => 2019-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16241 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15589731 [patent_doc_number] => 20200071400 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => CAR T Therapy through Uses of Co-stimulation [patent_app_type] => utility [patent_app_number] => 16/552521 [patent_app_country] => US [patent_app_date] => 2019-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12560 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16552521 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18134777 [patent_doc_number] => 11560430 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-24 [patent_title] => Anti-PD-1 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/543310 [patent_app_country] => US [patent_app_date] => 2019-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 25 [patent_no_of_words] => 19810 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 200 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16543310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16246140 [patent_doc_number] => 10745482 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-18 [patent_title] => Antibodies directed against ICOS and uses thereof [patent_app_type] => utility [patent_app_number] => 16/533038 [patent_app_country] => US [patent_app_date] => 2019-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 16274 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16533038 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16090535 [patent_doc_number] => 20200199254 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => IDENTIFICATION OF VSIG8 AS THE PUTATIVE VISTA RECEPTOR (V-R) AND USE THEREOF TO PRODUCE VISTA/VSIG8 AGONISTS AND ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 16/531968 [patent_app_country] => US [patent_app_date] => 2019-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 88025 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16531968 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16114429 [patent_doc_number] => 20200209237 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => DETECTION AND TREATMENT OF AUTOIMMUNE DISORDERS [patent_app_type] => utility [patent_app_number] => 16/532435 [patent_app_country] => US [patent_app_date] => 2019-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13987 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16532435 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15145009 [patent_doc_number] => 20190350982 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => Activation of Marrow Infiltrating Lymphocytes in Hypoxic Alternating with Normoxic Conditions [patent_app_type] => utility [patent_app_number] => 16/526656 [patent_app_country] => US [patent_app_date] => 2019-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6647 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16526656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16582880 [patent_doc_number] => 20210017282 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => TARGETED BINDING AGENTS AGAINST B7-H1 [patent_app_type] => utility [patent_app_number] => 16/519614 [patent_app_country] => US [patent_app_date] => 2019-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45845 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16519614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15618861 [patent_doc_number] => 20200079835 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-12 [patent_title] => B7-RELATED NUCLEIC ACIDS AND POLYPEPTIDES USEFUL FOR IMMUNOMODULATION [patent_app_type] => utility [patent_app_number] => 16/516225 [patent_app_country] => US [patent_app_date] => 2019-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40423 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16516225 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15993491 [patent_doc_number] => 20200172616 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => HUMAN ANTI-PD-1, PD-L1, AND PD-L2 ANTIBODIES AND USES THEREFOR [patent_app_type] => utility [patent_app_number] => 16/506840 [patent_app_country] => US [patent_app_date] => 2019-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37805 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16506840 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18233205 [patent_doc_number] => 11597754 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-07 [patent_title] => Use of the CD2 signaling domain in second-generation chimeric antigen receptors [patent_app_type] => utility [patent_app_number] => 16/460221 [patent_app_country] => US [patent_app_date] => 2019-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 23998 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16460221 [rel_patent_id] =>[rel_patent_doc_number] =>)